Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-05-17
2011-05-17
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000, C514S178000
Reexamination Certificate
active
07943602
ABSTRACT:
The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 μg of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors; and a pharmaceutically acceptable excipient. The term “15-hydroxytestosterones” encompasses both 15α-hydroxytestosterone (15α, 17β-dihydroxy-4-androsten-3-one) and 15β-hydroxytestosterone (15β, 17β-dihydroxy-4-androsten-3-one). Similarly, the term “16-hydroxytestosterones” encompasses both 16α-hydroxytestosterone hydroxytestosterone (16α, 17β-dihydroxy-4-androsten-3-one) and 16β-hydroxytestosterone (16β, 17β-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.
REFERENCES:
patent: 2793216 (1957-05-01), Murray et al.
patent: 6117446 (2000-09-01), Place
patent: 2.035.786 (1970-12-01), None
patent: 774064 (1957-05-01), None
patent: WO 00/74684 (2000-12-01), None
patent: WO 01/23405 (2001-04-01), None
Wood, et al., “Regio- and Stereoselective Metabolism of Two C19 Steroids by Five Highly Purified and Reconstituted Rat Hepatic Cytochrome P-450 Isozymes”, Journal of Biological Chemistry, 1983, 258 (14), pp. 8839-8847.
Yamazaki, “Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4in Human Liver Microsomes1”, Archives of Biochemistry and Biophysics,vol. 346, No. 1, 1997, pp. 161-169.
Allen et al., “The Reaction of Alkoxalylated Steroid Ketones with Dibenzoyl Peroxide. A Synthesis of 16β-Hydroxytestosterone”, J. Org. Chem. (1962), 27(12) 4681-4682.
Yamashita, et al. “Microbial 16β-Hydroxylation of Steroids withAspergillus niger”, Agr. Biol. Chem. (1976) 40 (3), 505-509.
Rosenbrock, et al., “Testosterone Metabolism in Rat Brain Is Differentially Enhanced by Phenytoin-Inducible Cytochrome P450 Isoforms”, J. of Neuroendocrinology, (1999) 11, 597-604.
Bennink Herman Jan Tijmen Coelingh
Bunschoten Evert Johannes
Van Der Linden René Frank
Javanmard Sahar
Padmanabhan Sreeni
Pantarhei Bioscience B.V.
The Webb Law Firm
LandOfFree
Pharmaceutical application of 15- or 16-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical application of 15- or 16-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical application of 15- or 16-substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692776